Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737925) titled 'LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan' on July 27.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Thomas Jefferson University

Condition: Prostate Cancer Metastatic Castrate Resistant Prostate Cancer

Intervention: Drug: Xaluritamig

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 2026

Target Sample Size: 30

To know more, visit https://clini...